![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics of Hepatitis C Virus Protease Inhibitor MK-5172 in Volunteers With Mild and Moderate Hepatic Impairment
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014
L Caro1, WW Yeh1, M Ho1, N Uemura1, Z Guo1, J Talaty1, C Reitmann1, IP Fraser1, A Testro2, P Angus2, T Marbury3, E Gane4, JR Butterton1
1Merck & Co., Inc., Whitehouse Station, NJ, USA; 2Centre for Clinical Studies, Melborne, VIC, Australia; 3Orlando Clinical Research Center, Orlando, FL, USA,4Auckland Clinical Studies, Auckland, New Zealand
![Pharm1.gif](../images/052514/052514-7/Pharm1.gif)
![Pharm2.gif](../images/052514/052514-7/Pharm2.gif)
![Pharm3.gif](../images/052514/052514-7/Pharm3.gif)
![Pharm4.gif](../images/052514/052514-7/Pharm4.gif)
![Pharm5.gif](../images/052514/052514-7/Pharm5.gif)
![Pharm6.gif](../images/052514/052514-7/Pharm6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|